BGI Genomics
Chinese genomics giant selling sequencing, testing, and lab services worldwide.
On the record
Checkpoint: US OMB decision on whether BGI makes the formal BCC list under the BIOSECURE Act
The call
BGI's home market keeps it standing while Western revenue shrinks under mounting US biosecurity restrictions.
BGI Genomics sequences DNA and stores genetic data, mainly serving China and other countries outside the Western alliance. Its business is shrinking fast: revenue dropped by half between 2022 and 2025, it lost money last year, and it pulled out of the U.S. and U.K. Competitor Illumina dominates globally, but cannot operate inside China, so BGI has that advantage at home. The real problem is a U.S. law called BIOSECURE that will restrict BGI's access to American technology and markets starting in 2027, which could hurt its ability to stay competitive even in Asia. What matters most: whether BGI can grow profitable new business in Saudi Arabia, Thailand, and other non-Western countries fast enough to replace the revenue it is losing in the West.
Why
01
AI pressure: None apparent. AI tools speed up genomic interpretation but don't replace BGI's sequencing hardware or lab services. Could AI do the core job? Unlikely.
02
Bigger players: Illumina. Illumina's NGS platforms dominate outside China; BGI already closed its US and UK subsidiaries in 2025. Could a giant copy it? Probably.
03
What protects it. About 85% of revenue stays inside mainland China, backed by state contracts, DNBSeq tech, and the national biobank.
What would change this call
August 22, 2026 Q2 earnings report. Shows whether Q1's +20% YoY revenue growth is a durable trend or a one-off bounce.
December 2026 US OMB BCC designation list scope for BGI Genomics. Determines how far US federal-contract restrictions expand beyond the current DoD 1260H listing.
EU, UK, or Australia issuing BIOSECURE-style restrictions on BGI contracts or data. Would show Western regulatory exclusion spreading beyond the US and hitting APAC growth channels.
December 2026 US OMB BCC designation list scope for BGI Genomics. Determines how far US federal-contract restrictions expand beyond the current DoD 1260H listing.
EU, UK, or Australia issuing BIOSECURE-style restrictions on BGI contracts or data. Would show Western regulatory exclusion spreading beyond the US and hitting APAC growth channels.
Key numbers
- FY2025 revenue RMB 3.71B, down 4% YoY
- Q1 2026 revenue up 20% YoY
- Americas revenue fell 34% to RMB 59.8M
Named risks
- BIOSECURE Act BCC designation due December 2026 could bar BGI from US federal-linked contracts.
- Multi-year revenue decline from RMB 7.05B (FY2022) to RMB 3.71B (FY2025) with continued net losses.
- Retreat from Western markets (US, UK subsidiary closures in 2025) shrinks addressable geography.
- Domestic Chinese commoditization pressure from Novogene and Berry Genomics on core sequencing services.
- GigaScience editorial board mass resignation in November 2025 over governance concerns.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Illumina | contesting | 70%+ global NGS share vs Illumina blocked from Chinese state health system, 2026-02-24 |
| Novogene | gaining on | domestic Chinese NGS services rival pressuring BGI on price as sequencing revenue shrinks |
| Berry Genomics | contesting | tracked as direct domestic comparable ticker on Chinese genomics platforms, 2024-07-03 |
| Thermo Fisher Scientific | contesting | competing Ion Torrent sequencing and integrated genomics workflows, per market report 2026-02-22 |
Questions people ask
- Is BGI Genomics profitable in 2026?
- No. BGI Genomics posted a net loss of about RMB 617 million for FY2025, and its trailing twelve months to March 31, 2026 still showed a loss of roughly RMB 573 million, even as Q1 2026 revenue rose 20% year over year, per genomeweb.com, April 28, 2026.
- Could AI replace BGI Genomics?
- Unlikely to replace it outright. BGI's core moat is wet-lab sequencing chemistry, its China National GeneBank biobank, and clinical regulatory approvals, none of which AI can replicate. BGI itself is building genomic AI, releasing Genos-Mutation and Genos-Reg foundation models in June 2026.
- Who is BGI Genomics' biggest competitor?
- Illumina is the dominant global rival, holding over 70% of the NGS instruments market per GenomeWeb, February 24, 2026, though it is barred from China's state health system while BGI itself is barred from the US via the December 18, 2025 BIOSECURE Act.
- Why did BGI Genomics close its US and UK subsidiaries in 2025?
- BGI Genomics shut GBI Diagnostics in the US and BGI Genomics UK in 2025 as part of an overseas business adjustment, coinciding with Americas revenue falling 34% to RMB 59.8 million and ahead of the December 18, 2025 BIOSECURE Act taking effect, per genomeweb.com, April 28, 2026.
- Who owns BGI Genomics?
- BGI Genomics is publicly traded on the Shenzhen Stock Exchange ChiNext board (ticker 300676) since July 14, 2017. Its top disclosed shareholder is Shenzhen Qianhai BGI Investment Enterprise at 7.73%, with the top 25 shareholders holding about 56.5% combined, per simplywall.st.
- What does the BIOSECURE Act mean for BGI Genomics?
- Enacted December 18, 2025 under the FY2026 NDAA, the BIOSECURE Act names BGI Group on the Defense Department's Section 1260H list as of June 9, 2026, a precursor to a formal Biotechnology Company of Concern designation due by December 2026, with US federal contracting restrictions phasing in through 2027 to 2028.
Timeline
- 2026-06-25BGI-Research releases Genos-Mutation and Genos-Reg genomic AI models trained on 636 genomes
- 2026-06-09DoD updated 1260H list adds BGI Group as Chinese military-linked company
- 2026-04-28FY2025 results: revenue RMB 3.71B (down 4%); Q1 2026 revenue up 20% YoY
- 2025-12-30BGI Group milestones report cites Genalive Saudi contract, Genos model release
- 2025-12-18BIOSECURE Act enacted as part of FY2026 NDAA
- 2025-09-22BGI Genomics launches AI-powered i99 health management platform
- 2025BGI closes GBI Diagnostics (US) and BGI Genomics UK subsidiaries
- 2017-07-14BGI Genomics lists on Shenzhen Stock Exchange ChiNext board
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- BGI Genomics Reports 20 Percent Rise in Q1 Revenue, 4 Percent Drop for Full-Year 2025 (2026-04-28)
- BGI Genomics (SHE) (2026-07-01)
- Earnings & Revenue Performance
- BGI Group Milestones 2025 (2025-12-30)
- 2025 Trends: Moving beyond diagnostics to proactive health management
- 300676) Company Profile & Description (2026-07-02)
- gurufocus.com (2026-07-24)
- BGI Investor Relations
- BIOSECURE Act Enacted (2026-05-13)
- Department of Defense Releases Updated 1260H List... (2026-06-09)
- Scientific Discoveries-BGI Group Official Website (2026-06-25)
- BGI Genomics taps AI to power healthcare transformation in Saudi Vision (2025-09-22)